Minnesota 2025-2026 Regular Session

Minnesota Senate Bill SF3294

Introduced
4/7/25  

Caption

Prescription drug transparency provisions modifications

Impact

If enacted, SF3294 would strengthen state statutes governing drug transparency, potentially leading to more regulated drug pricing practices. The aim is to level the playing field and improve access to affordable medications for residents reliant on the 340B program. Other significant changes include the introduction of fines for entities that fail to comply with the reporting requirements, further amplifying the need for accurate data on drug costs and sales, thus promoting better policy-making based on real-world data.

Summary

SF3294, introduced in 2025, aims to modify provisions related to prescription drug transparency in Minnesota. The bill focuses on enhancing the reporting requirements for covered entities, particularly those participating in the federal 340B drug pricing program. Under the proposed legislation, these entities would be mandated to submit detailed reports by April 1 of each year regarding medication acquisition costs, payments received, and the number of pricing units dispensed. This measure intends to provide greater oversight and data aggregation, helping stakeholders understand the financial mechanisms shaping drug pricing in the state.

Contention

Key points of contention surrounding SF3294 include concerns from healthcare providers regarding the feasibility of the new reporting standards, particularly for smaller healthcare entities that may struggle with the compliance burden. Additionally, there are fears that increased scrutiny on pricing data could deter manufacturers from participating in the 340B program altogether, which could ultimately undermine the intended benefits of the program. Opponents argue that while transparency is beneficial, it must be pursued in a way that does not hinder access to necessary medications or place undue burdens on critical healthcare services.

Companion Bills

MN HF3054

Similar To Prescription drug transparency provisions modified.

Previously Filed As

MN SF4861

340B covered entities reporting requirements modifications and reports to the legislature requirement

MN HF294

Manufacturers required to report and maintain prescription drug prices, filing of health plan prescription drug formularies required, health care coverage provisions modified, prescription benefit tool requirements established, and prescription drug benefit transparency and disclosure required.

MN SF5329

Prescription drugs price increases and reporting requirements provisions

MN SF3722

Prescription drug price transparency act provisions amendments

MN HF4755

Health; 340B covered entity reporting requirements modified.

MN SF49

Health insurance provisions modifications and appropriations

MN SF328

Manufacturers requirement to report and maintain prescription drug prices

MN SF3333

Medical assistance prescription drug reimbursement definition of usual and customary price modification

MN SF4330

Definition modification of usual and customary price for the purposes of medical assistance prescription drug reimbursement

MN HF17

Generic or off-patent drugs; excessive price increases prohibited, attorney general authorized to take action against price increases, sale withdrawal prohibited, prescription drug affordability board and advisory council established, prescription drug cost reviews and remedies provided, and money appropriated.

Similar Bills

MN HF3054

Prescription drug transparency provisions modified.

MN SF2477

Health insurance, Medicare supplement benefits and prescription drugs provisions modifications

MN SF3063

Reverse auction procurement requirement modification for SEGIP pharmacy benefit contracts

MN SF102

Hospitals and health care providers gross tax revenue repeal and technical changes made

MN SF3269

Gross revenues tax on hospitals and health care providers repeal

MN SF1480

Gross revenues tax on hospitals and health care providers repeal

MN SF1081

Gross revenues tax repeal on hospitals and health care providers

MN HF2851

Reverse auction procurement requirement for SEGIP pharmacy benefit contracts modified, use of spread pricing by pharmacy benefit managers prohibited, license application fees increased, fiduciary duties imposed, and money appropriated.